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Background-—The reasons for China’s high stroke prevalence are not well understood. The cardiovascular risk factor profiles of
China and the United States have not been directly compared in nationally representative population samples.
Methods and Results-—Using data from the CHARLS (China Health and Retirement Longitudinal Study) and the NHANES (US
National Health and Nutrition Examination Survey), we compared cardiovascular risk factors from 2011 to 2012 among people
aged 45 to 75 years between the 2 countries (China, 12 654 people; United States, 2607 people): blood pressure, cholesterol,
body mass index, waist circumference, fasting plasma glucose, hemoglobin A1c, and high-sensitivity C-reactive protein. Compared
with the United States, China had a lower prevalence of hypertension but a higher mean blood pressure and a higher proportion of
patients with severe hypertension (≥160/100 mm Hg) (10.5% versus 4.5%). China had substantially lower rates of hypertension
treatment (46.8% versus 77.9%) and control (20.3% versus 54.7%). Dyslipidemia was less common in China, but lipid levels were
not significantly different because dyslipidemia awareness and control rates in China were 3- and 7-fold lower than US rates,
respectively. High-sensitivity C-reactive protein, body mass index, and waist circumference were significantly lower in China than in
the United States. Clustering of hypertension with other cardiovascular risk factors was more common in China.
Conclusions-—Hypertension is more common in the United States, but blood pressure levels are higher in China, which may be
responsible for China’s high stroke prevalence. The low rates of awareness, treatment, and control of hypertension provide an
exceptional opportunity for China to reduce risk in its population. ( J Am Heart Assoc. 2018;7:e007462. DOI: 10.1161/JAHA.
117.007462.)
Key Words: cardiovascular diseases prevention • cardiovascular diseases risk factors • global disparities • international
comparison
S troke is the leading cause of death in China, in contrastwith much of the rest of the world, where coronary heart
disease predominates.1 The explanation for the high preva-
lence of stroke in China is not known. One hypothesis is that
China’s population-wide risk factor profile is weighted toward
stroke rather than coronary heart disease. The question is
whether the risk factor profile in China is tilted toward
hypertension, which has a stronger link with stroke risk than
with coronary heart disease risk,2 rather than, for example,
elevated lipid levels, which have stronger associations with
coronary heart disease.3 However, there have been no recent
studies on direct comparisons of the risk factor profile of
China and the United States, a country in which coronary
disease is more common than stroke.1 Such a comparison
could provide evidence about whether the elevated stroke risk
in China is a result of its risk factor profile or some other
susceptibility that is not captured by traditional risk factors.
The World Health Organization MONICA (Multinational
Monitoring of Trends and Determinants in Cardiovascular
Disease) Project and the InterAsia study are the 2 landmark
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studies that have previously described modifiable cardiovas-
cular risk factors in China and the United States, but they
were conducted >15 years ago.4,5 Many recent studies have
examined risk factors in the respective countries, but we lack
a direct comparison based on recent representative national
samples and comparable survey methods in the 2 countries.
Nevertheless, the prior literature provides some indication
that the risk profiles may be different. In studies from China,
the prevalence of hypertension is high; although lipid
abnormalities and diabetes mellitus are increasing, they tend
to be lower compared with the United States.6 In the United
States, hypertension is also common, but so are obesity,
dyslipidemia, and diabetes mellitus.7,8 If there are differences
in the risk factor profiles of the 2 countries, it is also not clear
if the differences are a result of a contrast in the underlying
prevalence of the risk factors or marked differences in
treatment and control of the risk factors. The rates of
treatment and control of cardiovascular risk factors in the
United States have increased markedly in recent decades,
whereas studies suggest that China is lagging in risk factor
management.8–10 These prior studies, however, are not
suitable for country-to-country comparison because of differ-
ences in the study samples and the survey methods.
Accordingly, we sought to compare the risk factor profile of
China and the United States using data with representative
population-based samples from each country and similar
survey methods. Our hypothesis was that the differences in
cardiovascular disease outcomes between the 2 countries are
attributable to their differences in their risk factor profiles and
that hypertension would be expected to predominate in China,
whereas other risk factors might be more prevalent in the
United States. Moreover, we investigated whether there were
also country differences in awareness, treatment, and control
of hypertension and lipid abnormalities that may explain any
differences in the risk factor profiles. To pursue these
questions, we used study data from the CHARLS (China
Health and Retirement Longitudinal Study),11 a nationally
representative survey of Chinese adults, and from the
NHANES (US National Health and Nutrition Examination
Survey).12 We specifically addressed 5 major cardiovascular
risk factors: blood pressure, cholesterol, body mass index
(BMI) and waist circumference, blood glucose, and high-
sensitivity C-reactive protein (hs-CRP). We focused on survey
participants aged 45 to 75 years for the period from 2011 to
2012.
Methods
Data Sources
To compare China and the United States, we used 2 nationally
representative publicly available survey data sets: CHARLS
from China and NHANES from the United States for the 2011
to 2012 period. Both CHARLS and NHANES collected data
from in-person interviews, physical examinations, and blood
specimens.11,12 Both CHARLS and NHANES are public
databases, and the data, analytic methods, and study
materials have been made available to other researchers for
purposes of reproducing the results or replicating the
procedure.11,12 NHANES was approved by the National Center
for Health Statistics Ethics Review Board, and CHARLS was
approved by the ethical review committee of Peking Univer-
sity; subjects in both studies gave informed consent.
The China Health and Retirement Longitudinal Study
CHARLS is a nationally representative longitudinal survey of
adults aged ≥45 years in China. A detailed description of
CHARLS was published previously.13 Briefly, the baseline
survey, conducted in 2011 and 2012, used a multistage
probability-sampling strategy with random samples drawn at
county, neighborhood, household, and respondent levels.14
Participants were enrolled from 150 counties/districts and
450 villages/resident committees in 28 provinces across
China. Face-to-face household interviews were conducted by
trained personnel to collect information on sociodemographic
characteristics, self-reported health status, and medical
history. The interviewers also carried equipment for anthro-
pometric and other physical measurements, including height,
weight, and blood pressure. After completing the household
interviews, respondents were invited to a local office of the
China Center for Disease Prevention and Control or to
township hospitals, where trained nurses drew fasting blood
samples. Response rate for the CHARLS interview was 80.5%.
Clinical Perspective
What Is New?
• Using a nationally representative population sample, we
showed that China and the United States had different
cardiovascular risk factor profiles, with hypertension being
more common in the United States but China having higher
blood pressure levels.
• Dyslipidemia is less common in China, but lipid levels are
similar.
• China is less advanced in the epidemiological transition, but
because of undertreatment and poor control, the actual
population levels are worse for blood pressure and not so
different for lipids.
What Are the Clinical Implications?
• The low rates of awareness, treatment, and control of
hypertension provide an exceptional opportunity for China
to reduce risk in its population.
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The US National Health and Nutrition Examination
Survey
NHANES is an annual nationally representative survey of the
US noninstitutionalized population identified through a strat-
ified, multistage, probability-sampling design. Hispanics, non-
Hispanic blacks, non-Hispanic Asians, and older adults were
oversampled to provide stable estimates for these groups.
Household interviews were conducted by trained personnel
to collect information on health and sociodemographic
characteristics. After participating in the interview, respon-
dents were invited to a mobile center, where standardized
physical examinations were conducted. Blood samples were
also drawn from a random subset of participants. Response
rates for the NHANES interview and physical examination
were 72.6% and 69.5%, respectively, for participants of all
ages.
Sample construction
To ensure comparable cohorts, our analysis focused on
participants who were 45 to 75 years old: 15 946 partici-
pants in CHARLS and 2607 participants in NHANES. We
excluded participants >75 years to focus on the age range
commonly considered for premature event and mortality. For
this analysis, we also excluded participants who were missing
covariate data, such as age, sex, or sample weight (20.6% of
participants for CHARLS and 0% of participants for NHANES),
risk factor data, or both (Figure S1). Our analysis included
12 654 participants in CHARLS and 2607 participants in
NHANES, aged 45 to 75 years.
Blood Pressure Measurements
In CHARLS, an electronic blood pressure monitor (Omron
HEM-7112; Omron [Dalian] Co, Dalian, China) measured blood
pressure 3 times on the patient’s right upper arm after
5 minutes of seated rest. In NHANES, after the patient had
5 minutes of seated rest, a physician took 3 consecutive
measurements using an appropriately sized cuff (Baumanome-
ter calibrated mercury true gravity sphygmomanometer cuffs;
W.A. Baum Co, Inc, Copiague, NY) and a stethoscope
(Littmann Cardiology III Stethoscopes; 3M, St Paul, MN). For
both data sets, we calculated the mean value of the last 2
blood pressure readings for each participant. Hypertension
was defined as a mean systolic blood pressure of
≥140 mm Hg, a mean diastolic blood pressure of
≥90 mm Hg, or self-reported use of antihypertensive medi-
cation. Awareness of hypertension was defined as a self-
reported physician diagnosis of hypertension or self-reported
use of antihypertensive medication. Treated hypertension was
defined as self-reported use of antihypertensive medication.
Controlled hypertension was defined as a mean systolic blood
pressure of ≤140 mm Hg, and a mean diastolic blood
pressure of ≤90 mm Hg, among people with previously
diagnosed hypertension.
Height, Weight, and Waist Circumference
Measurements
In CHARLS, trained observers measured height and weight
using a stadiometer (Seca 213; Seca Trading Co, Hangzhou,
China) and digital scale (Omron HN-286; Omron Corporation,
Kyoto, Japan). Waist circumference was measured at navel
level using soft tape. In NHANES, height and weight were
recorded using a stadiometer and a digital scale linked to the
Integrated Survey Information System anthropometry soft-
ware. Waist circumference was measured just above the iliac
crest using steel tape. BMI was calculated as weight in
kilograms divided by height in meters squared. Overweight for
both cohorts was defined as a BMI of 25.0 to <30 kg/m2;
obesity was defined as a of BMI of ≥30.0 kg/m2. In a
sensitivity analysis, we defined obesity as a BMI of ≥28.0 kg/
m2 and overweight as a BMI of 24.0 to <28.0 kg/m2 for the
Chinese cohorts based on recommendations of the Working
Group on Obesity in China.15
Serum Measurements
CHARLS and NHANES collected blood samples from both
fasting and nonfasting participants. Total cholesterol (TC),
high-density lipoprotein cholesterol (HDL-C), and hemoglobin
A1c (HbA1c) were tested for all blood samples, whereas low-
density lipoprotein cholesterol (LDL-C), triglycerides, and
fasting plasma glucose were measured for a subset of fasting
blood samples. Both surveys analyzed TC, HDL-C, triglyc-
erides, and fasting glucose using the enzymatic method
(CHARLS: Youanmen Center for Clinical Laboratory of Capital
Medical University; NHANES: Roche/Hitachi Modular P
Chemistry Analyzer [Roche Diagnostics, Indianapolis, IN]).
LDL-C was measured directly from biospecimens in CHARLS
and was derived using the Friedewald equation in NHANES.16
In a sensitivity analysis, we calculated LDL-C in the CHARLS
cohort and compared that with NHANES. HbA1c was
measured by Boronate affinity high-performance liquid chro-
matography method in CHARLS and by Tosoh G8 Glycohe-
moglobin Analyzer (Tosoh Bioscience, Inc, South San
Francisco, CA) in NHANES. hs-CRP was quantified by
immunoturbidimetric assay (Youanmen Center for Clinical
Laboratory of Capital Medical University) in CHARLS and by
latex-enhanced nephelometry (Siemens/Behring BNII; Sie-
mens Heathcare Diagnostics, Inc, New Castle, DE) in
NHANES. For the United States, we used hs-CRP measure-
ment from NHANES 2009 to 2010 given that it was not
available in NHANES 2011 to 2012. To ensure the accuracy of
serum measurements, the CHARLS laboratory used quality
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control samples daily during the testing of all samples and
was quality assured by the National Center for Clinical
Laboratories, China Ministry of Health. Appropriate quality
control and Quality Assurance protocol were followed in
NHANES, as discussed in the NHANES Laboratory/Medical
Technologists Procedures Manual.12 The rigorous quality
control standards of both CHARLS and NHANES generated
the best-available and comparable data for the purposes of
the present study.
Dyslipidemia was defined as either or combination of TC
≥240 mg/dL, LDL-C ≥160 mg/dL, HDL-C <40 mg/dL,
triglycerides ≥200 mg/dL, or self-reported use of lipid-
lowering medication, according to the 2007 Chinese guide-
lines on the prevention and treatment of dyslipidemia.17
Awareness of dyslipidemia was defined as a self-reported
physician diagnosis of dyslipidemia or self-reported use of
lipid-lowering medication. Treated dyslipidemia was defined
as self-reported use of lipid-lowering medication. Controlled
dyslipidemia was defined as TC <240 mg/dL, LDL-C
<160 mg/dL, HDL-C ≥40 mg/dL, and triglycerides
<200 mg/dL among people with dyslipidemia.
Diabetes mellitus was defined as fasting plasma glucose
≥126 mg/dL, HbA1c ≥6.5%, a self-reported physician diag-
nosis of diabetes mellitus, or self-reported use of diabetes
mellitus medication, according to American Diabetes Associ-
ation definition.18 Treated diabetes mellitus was defined as
self-reported use of diabetic medication. Controlled diabetes
mellitus was defined as HbA1c of <7% among people with
diabetes mellitus or lower among people with diabetes
mellitus.19,20 Elevated CRP was defined as hs-CRP ≥3 mg/L.
Sociodemographic and Clinical Variables
We quantified participants’ socioeconomic status by marital
status, highest level of education, health insurance, and
employment status. Although the questions from the 2 surveys
were not identical, we created discrete categories and coded
variables that were consistently defined for the 2 surveys.
Specifically, education was categorized into primary school or
below, middle school, high school, and college or university.
Employment status was categorized into employed, self-
employed/agricultural work/family business, or not working/
retired. Marital status was categorized into married or wid-
owed/separated/divorced/single. We also reported other
cardiovascular risk factors and comorbidities, such as history
of heart disease or stroke, excess alcohol consumption (>5
drinksperweek), andsmokingstatus.Heartdiseasewasdefined
as physician-diagnosed heart attack, coronary heart disease,
angina, congestive heart failure, and other heart problems. We
categorized smokers into current, former, and never smokers.
Current cigarette smokers were defined as those who had
smoked ≥100 cigarettes over their lifetime and smoked at the
timeof the interview; formersmokersweredefinedas thosewho
had smoked ≥100 cigarettes but did not currently smoke; and
never smokersweredefinedas thosewhohadnot smoked≥100
cigarettes in their lifetime.Wealso reported the averagenumber
of cigarettes per day among current smokers.
Statistical Analysis
We summarized participants’ sociodemographic and clinical
characteristics using descriptive statistics, reporting the
medians and interquartile ranges for continuous variables,
and proportions and accompanying 95% confidence intervals
for categorical variables. We determined statistical differ-
ences between China and the United States using v2, Student
t, and Wilcoxon rank-sum tests, when appropriate.
To compare distributions of cardiovascular risk factors in
China and the United States, we first estimated the means
and SEMs of all biomarkers for the 2 countries. We accounted
for the complex survey design and sample weights of CHARLS
and NHANES in our analysis. The distributions of blood
pressure, lipid profiles, and blood glucose by treatment status
were plotted and visualized. For hypertension and dyslipi-
demia, we estimated the prevalence, awareness, treatment,
and control rates for the 2 countries. Mean BMI, prevalence of
BMI categories, mean fasting plasma glucose, prevalence of
diabetes mellitus, mean hs-CRP, and prevalence of elevated
hs-CRP were estimated and visualized by age group and sex
for both countries.
We also report clustering of the 4 cardiometabolic risk
factors (0, 1, 2, and ≥3 for hypertension, dyslipidemia,
diabetes mellitus, overweight, and obesity), awareness of 0, 1,
2, or 3 risk factors (hypertension, dyslipidemia, and diabetes
mellitus), and control of 0, 1, 2, or 3 factors (hypertension,
dyslipidemia, and diabetes mellitus). Clustering was assessed
by counting the number of risk factors per person. All
analyses were conducted with R 3.10 (The R Foundation for
Statistical Computing, Vienna, Austria).
Results
Characteristics of the Study Population
After excluding people with missing data on age, sex, and
sample weight, our study sample comprised 12 654 partic-
ipants in China (representing 404 million people) and 2607
participants in the United States (representing 105 million
people), aged 45 to 75 years.21,22 Table 1 summarizes the
distributions of sociodemographic and clinical characteristics.
The age and sex distributions of participants did not differ
significantly between China and the United States. The
median age of both samples was 57 years; 48.4% of the
Chinese sample and 47.6% of the US sample were women.
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The age-sex distributions in CHARLS and NHANES aligned
with the distributions in the Chinese and US census data,
respectively.
Compared with the US sample, the Chinese sample had a
lower socioeconomic status. Most (61.8%) of the Chinese
participants had education of primary school or below, and
few (2.7%) participants had attended college or university; in
the United States, 5.9% of participants had education of
primary school or below, and 62.3% had attended college or
university. Fewer people were not working or retired in China
(32.9%) than in the United States (41.1%). More Chinese
participants were married (88.7%) and had insurance (91.1%)
than US participants (60.5% and 85.6%, respectively). In terms
of medical history, history of heart disease and stroke was
less common for Chinese participants compared with US
participants.
Smoking and excess drinking were more common in China
than in the United States. Specifically, the Chinese sample
had 1.5 times more current smokers than the US sample
(30.0% versus 19.4%). Chinese current smokers smoked
significantly more cigarettes per day (median, 20 [interquartile
range, 10–20]) compared with US current smokers (median,
12 [interquartile range, 7–20]). There were fewer former
smokers (9.4% versus 29.9%) and more never smokers (60.6%
versus 50.7%) in China than in the United States.
Blood Pressure and Hypertension
Blood pressure distributions differed significantly between the
2 countries. Overall, mean blood pressure was higher in China
(systolic blood pressure [SEM]/diastolic blood pressure
[SEM], 130.0 [0.38]/76.4 [0.24] mm Hg) than in the United
States (125.1 [0.72]/72.5 [0.41] mm Hg) (P<0.001)
(Table 2). Although hypertension was less common in China
than in the United States (38.6% versus 46.9%), severe blood
pressure levels (≥160/100 mm Hg) were 2.5 times more
common in China than in the United States (10.5% versus
4.5%) (Table 3). Among people with hypertension, fewer
people in China than in the United States were aware of their
hypertension status, received blood pressure–lowering med-
ications, and achieved blood pressure control. Specifically,
only slightly more than half (56.1%) of hypertensive Chinese
people were aware of their hypertensive status, compared
with 84.2% in the United States. Only 46.8% of hypertensive
Chinese people were taking prescribed medications to lower
their blood pressure, compared with 77.9% in the United
States. Even among treated patients, the Chinese population
had higher blood pressure and greater variation in blood
pressure distribution than did US adults (Figure 1A). Among
the overall sample, people with treated hypertension, and
people with untreated hypertension, China had a greater
proportion of extremely hypertensive people compared with
the United States (Figure 1A). Only 20.3% of hypertensive
Chinese people achieved blood pressure control, compared
with 54.7% in the United States (Table 3).
Table 1. Characteristics of the Study Populations in China
and the United States From 2011 to 2012
Characteristics
China
(N=12 654)
United States
(N=2607)
P Value
for Difference
Age, y
Median (IQR) 57 (50–64) 57 (51–64) 0.05
45–54 39.1 41.0
55–64 40.0 37.4
65–74 20.9 21.6
Sex
Men 48.4 47.6 0.64
Women 51.6 52.3
Education
Primary school or below 61.8 5.9 <0.01
Middle school 23.8 10.6
High school 11.7 21.1
College or university 2.7 62.3
Employment status
Employed 16.5 50.0 <0.01
Self-employed/agricultural
work/family business
50.6 8.9
Not working/retired 32.9 41.1
Marital status
Married 88.7 60.5 <0.01
Widowed, separated,
divorced, or single
11.3 39.5
Health insurance
Yes 91.1 85.6 <0.01
No 8.9 14.4
Medical history
Heart disease* 11.5 12.4 <0.01
Stroke 2.2 3.7 0.01
Health behavior
Had >5 drinks per week 12.2 12.1 <0.01
Smoking
Current smoker 30.0 19.4 <0.01
Former smoker 9.4 29.9
Never smoker 60.6 50.7
No. of cigarettes per day
among current smokers,
median (IQR)
20 (10–20) 12 (7–20) <0.01
Data are given as percentage unless otherwise indicated. IQR indicates interquartile range.
*Heart disease was defined as physician-diagnosed heart attack, coronary heart disease,
angina, congestive heart failure, and other heart problems.
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Lipid Profile, Dyslipidemia, Glucose, and Diabetes
Mellitus
Overall, lipid and glucose levels in China were not significantly
different from or were slightly favorable compared with those
in the United States. China has lower mean (SE) levels of TC,
LDL-C, and triglycerides (192.4 [0.58], 115.5 [0.6], and 135.3
[1.71] mg/dL, respectively) than in the United States (203.5
[1.25], 119.9 [1.62], and 139.9 [7.58] mg/dL, respectively)
(P<0.001) (Table 2 and Figure 1B). In contrast, HDL-C was
significantly lower in China (50.0 [0.25] mg/dL) than in the
United States (54.0 [0.75] mg/dL) (P<0.001). Although fewer
participants in China had dyslipidemia than in the United
States (42.7% versus 56.8%), fewer Chinese people with
dyslipidemia were aware of their lipid status, received lipid-
modifying medications, and achieved lipid control goals.
Among people with dyslipidemia, awareness was 3-fold higher
in the United States than in China (73.3% versus 19.6%), and
treatment rate was 4-fold higher in the United States than in
China (54.1% versus 13.2%). Most notably, among people with
dyslipidemia, control rates were 7-fold higher in the United
States than in China (35.7% versus 4.6%; Table 3). The
dominant components of dyslipidemia differed between the 2
countries: in the United States, high TC in men and low HDL-C
in women; in China, low HDL-C and high triglycerides in both
men and women (Figure 2). In a sensitivity analysis in which
we defined high cholesterol as TC ≥240 mg/dL, LDL-C
≥160 mg/dL, or use of lipid-modifying medication, we found
results similar to those for dyslipidemia. We conducted a
sensitivity analysis using calculated LDL-C in the CHARLS
cohort and found that the results do not differ importantly
from the main analysis that was conducted using measured
values of LDL-C in the CHARLS cohort.
Fasting plasma glucose levels in China have reached levels
that were not significantly different from those in the United
States. Mean (SEM) fasting plasma glucose was 109.6
(0.49) mg/dL in China and 109.5 (2.11) mg/dL in the United
States (P=0.97) (Table 2). Mean (SEM) HbA1c was lower in
China than in the Unites States (5.3% [0.01%] versus 5.8%
[0.03%]; P<0.01). Diabetes mellitus affected similar propor-
tions of Chinese and US participants (16.8% and 19.3%,
respectively; Figure 3). The distributions of fasting plasma
glucose in the overall sample, among nondiabetic participants,
and among people with untreated diabetes mellitus also were
similar in both countries (Figure 1C). Among people being
treated for diabetes mellitus, although fasting plasma glucose
levels were lower in China than in the United States, only 5%
of people with diabetes mellitus were being treated in China,
compared with 20% in the United States.
BMI, Waist Circumference, Overweight and
Obesity, and hs-CRP
The Chinese sample had lower BMI, lower waist circumfer-
ence, a lower proportion of overweight and obesity, and
lower hs-CRP levels compared with the US sample. Chinese
participants were shorter (mean, 159.0 [SEM, 0.15] cm) and
weighed less (mean, 61.0 [SEM, 0.48] kg) than US partici-
pants (mean, 168.0 [SEM, 0.36] cm; and mean, 83.3 [SEM,
0.93] kg, respectively) (P<0.001) (Table 2). BMI and waist
Table 2. Biomarker Distributions in China and the United States From 2011 to 2012
Metrics China (N=12 654)* United States (N=2607)* Difference in Mean (95% CI) P Value for Difference
SBP, mm Hg 130.0 (0.38) 125.1 (0.72) 4.9 (3.3 to 6.5) <0.001
DBP, mm Hg 76.4 (0.24) 72.5 (0.41) 3.9 (3 to 4.8) <0.001
TC, mg/dL 192.4 (0.58) 203.5 (1.25) 11.1 (13.8 to 8.4) <0.001
LDL-C, mg/dL 115.5 (0.6) 119.9 (1.62) 4.4 (7.8 to 1) <0.001
HDL-C, mg/dL 50.0 (0.25) 54.0 (0.75) 4 (5.5 to 2.5) <0.001
Triglycerides, mg/dL 135.3 (1.71) 139.9 (7.58) 4.6 (19.8 to 10.6) 0.37
FPG, mg/dL 109.6 (0.49) 109.5 (2.11) 0.1 (4.1 to 4.3) 0.97
HbA1c, % 5.3 (0.01) 5.8 (0.03) 0.5 (0.6 to 0.4) <0.001
Height, cm 159.0 (0.15) 168.0 (0.36) 9 (9.8 to 8.2) <0.001
Weight, kg 61.0 (0.48) 83.3 (0.93) 22.3 (24.4 to 20.2) <0.001
Waist circumference, cm 84.5 (0.73) 101.8 (0.74) 17.3 (19.3 to 15.3) <0.001
BMI, kg/m2 24.0 (0.18) 29.4 (0.33) 5.4 (6.1 to 4.7) <0.001
hs-CRP, mg/L 2.6 (0.08) 3.9 (0.25) 1.3 (1.8 to 0.8) <0.001
BMI indicates body mass index; CI, confidence interval; DBP, diastolic blood pressure; FPG, fasting plasma glucose; HbA1c, hemoglobin A1c; HDL-C, high-density lipoprotein cholesterol;
hs-CRP, high-sensitivity C-reactive protein; LDL-C, low-density lipoprotein cholesterol; SBP, systolic blood pressure; and TC, total cholesterol.
*Data are given as mean (SEM).
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circumference were much lower in China than in the United
States (BMI, mean, 24.0 [SEM, 0.18] kg/m2 versus 29.4 [SE,
0.33] kg/m2; waist circumference, mean, 84.5 [SEM,
0.37] cm versus 101.8 [SEM, 0.74] cm; P<0.001 for both).
Across all age and sex groups, overweight and obesity were
less common in China (28.0% overweight and 6.4% obese)
than in the United States (36.5% overweight and 38.6%
obese; Figure 4). In a sensitivity analysis in which obesity
was defined as a BMI of ≥28.0 kg/m2 and overweight was
defined as a BMI of 24.0 to <28.0 kg/m2 in the Chinese
cohort, 30.8% of the Chinese sample were overweight and
13.4% were obese. The Chinese sample had a lower median
hs-CRP (interquartile range) and a lower proportion of
elevated CRP (hs-CRP ≥3 mg/L) than the US sample (China,
1.0 [0.5–2.2] mg/L and 17.9%; versus US, 1.8 [0.7–
4.1] mg/L and 35.3%) (Table 2 and Figure 5). For both
sexes, the hs-CRP distributions showed a leftward shift for
Chinese participants compared with US participants (Fig-
ure 5). Across all age groups, both sexes had much lower
proportions of elevated CRP in China (19.2% in men and
16.7% in women) than in the United States (29.0% in men
and 41.3% in women; Figure 5).
Clustering of Risk Factors
Clustering of risk factors was less common in China than in
the United States, but clustering of hypertension with other
risk factors was more common in China than in the United
States. Overall, 31.4% of the Chinese sample and 10.6% of the
US sample did not have any of the cardiometabolic risk
factors (hypertension, dyslipidemia, diabetes mellitus, over-
weight, and obesity; Figure 6). The most common pairs of
clustered risk factors were hypertension and dyslipidemia in
China (17.8%), whereas dyslipidemia and overweight and
obesity were more commonly paired in the United States
(42.3%). Of the Chinese sample, 32.6%, 22.7%, and 13.3% had
1, 2, and ≥3 of these risk factors, respectively, compared with
24.2%, 30.7%, and 34.5% in the United States. Among people
with all 3 conditions of hypertension, dyslipidemia, and
diabetes mellitus, 16.3%, 26.9%, 27.4%, and 28.2% of the
Table 3. Prevalence, Awareness, Treatment, and Control of Hypertension and Dyslipidemia, in China and the United States, From
2011 to 2012
Variable China, % United States, %
Hypertension (SBP ≥140 mm Hg, DBP ≥90 mm Hg, or taking antihypertensive medication)
Among all people
Prevalence of hypertension 38.6 46.9
Prevalence of severe hypertension (≥160/100 mm Hg) 10.5 4.5
Among people with hypertension
Awareness of hypertension 56.1 84.2
Treatment rate of hypertension 46.8 77.9
Control rate of hypertension 20.3 54.7
Dyslipidemia (TC ≥240 mg/dL, LDL-C ≥160 mg/dL, HDL-C <40 mg/dL, TG ≥200 mg/dL, or taking lipid-modifying medication)
Among all people
Prevalence of dyslipidemia 42.7 56.8
Among people with dyslipidemia
Awareness of dyslipidemia 19.6 73.3
Treatment rate of dyslipidemia 13.2 54.1
Control rate of dyslipidemia 4.6 35.7
High cholesterol (TC ≥240 mg/dL, LDL-C ≥160 mg/dL, or taking cholesterol-modifying medication)
Among all people
Prevalence of high cholesterol 17.3 45.8
Among people with high cholesterol
Awareness of high cholesterol 37.7 84.3
Treatment rate of high cholesterol 31.1 67.1
Control rate of high cholesterol 26.5 57.2
DBP indicates diastolic blood pressure; SBP, systolic blood pressure; and TC, total cholesterol.
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Figure 1. Distribution of blood pressure (A), lipids (B), and fasting plasma glucose (C), by treatment status, in China and the United
States (US), from 2011 to 2012. HDL indicates high-density lipoprotein; and LDL, low-density lipoprotein.
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Chinese sample were aware of 0, 1, 2, or 3 of their risk
factors, compared with 3.6%, 7.0%, 22.4%, and 67.1% in the
United States; 49.9%, 38.2%, 11.3%, and 0.5% of the
Chinese sample had controlled 0, 1, 2, or 3 risk factors,
compared with 13.9%, 48.0%, 21.8%, and 15.3% in the
United States.
Discussion
We demonstrated that China and the United States had
different cardiovascular risk factor profiles, with hypertension
being more common in the United States, but China having
higher blood pressure levels. Dyslipidemia is less common in
China, but lipid levels are similar. China is less advanced in
the epidemiological transition, but because of undertreatment
and poor control, the actual population levels are worse for
blood pressure and not so different for lipids. Given that
hypertension has a stronger association with stroke than with
coronary heart disease,2 our findings suggest that hyperten-
sion may be responsible for China’s high stroke prevalence
and it is a much more important cardiovascular risk factor in
China than it is in the United States.
Hypertension is less common in China but poorly treated,
whereas in the United States hypertension is more common
but treatment is also more pervasive and population blood
pressure is declining because of improvements in treatment
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Figure 1. Continued.
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and control.8 The underdetected and undertreated hyperten-
sion represents an enormous opportunity for China because
the most important risk factor for stroke, which is the most
common cause of death in the country, is modifiable. The
United States has been successful in mitigating the burden of
hypertension by integrating screening and management of
hypertension into routine primary healthcare practice, as well
as providing affordable and effective medications.23 China
has the opportunities to mimic the success seen in the
United States, given the country’s health infrastructure,
particularly in primary care. Free screening and routine
management of hypertension have been provided since
China’s 2009 health reform.24,25 Efforts are needed to scale
up screening and use of antihypertensive medications as a
part of expanding and improving primary care. Moreover,
health workers and primary care physicians need to be better
trained on hypertension guidelines, diagnosis, and treatment.
Structured physician education programs, along with a
feedback system, can reduce clinical inertia, improve guide-
line adherence, and enhance hypertension diagnosis and
treatment.26–28 Improved health insurance, a national essen-
tial drug system, and other mechanisms to remove financial
barriers to health care and access to affordable drugs have
been implemented in the past decade.29 Notably, differences
in socioeconomic status and education between the 2
countries may contribute to the differences in hypertension
measures.30,31 Therefore, promoting a public education
program of the general population may also help to improve
hypertension awareness and treatment in China. However, in
our analysis of a recent national cardiovascular screening
project in China, we did not find any population subgroup
with a remarkably better control rate32,33; this suggests that
improving awareness and treatment through improving
education is likely necessary, but not sufficient, to achieve
better control in China. A fundamental structural change is
needed to address uncontrolled hypertension in China. The
issues may have to do with the need for screening and
education, supplemented by protocols and policies that
ensure provision of adequate treatment and access to
affordable medications.
Lipid and glucose levels in China do not differ significantly
from, or are slightly more favorable, compared with those in
the United States. An explanation is that, similar to
hypertension, dyslipidemia is less common in China (42.7%)
but poorly treated, whereas in the United States, dyslipidemia
is more common (56.8%) but treatment is also more common.
As lipid levels in China begin to approach levels in the United
States, promoting the use of effective cholesterol-modifying
medications (eg, statins) and a healthy lifestyle is critical to
preventing this risk factor from contributing to increased
prevalence of coronary heart disease in China in the future.
Similarly, as fasting plasma glucose levels in China increase,
promoting a healthy lifestyle is critical to preventing increased
prevalence of diabetes mellitus. BMI and elevated hs-CRP are
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lower in China than in the United States, which suggests that
they play less dominant roles in China’s overall risk profile and
represent less opportunity for improvement in China than in
the United States.
Our study is distinctive in using survey data from large
representative samples that allow for calculation of nationally
representative estimates. CHARLS and NHANES used simi-
larly standard protocols and instruments; their vigorous
quality-assurance programs ensured that high-quality data
were collected. In addition, we applied consistent inclusion
and exclusion criteria to the 2 data sets, thereby ensuring that
our results for each data set were directly comparable. Past
studies, such as the World Health Organization MONICA
Project, have described population risk factor levels and
cardiovascular disease incidence in China and the United
States using standardized methods.4 However, the MONICA
Project was conducted from 1979 to 1996, and it did not
address the awareness, treatment, and control rates of
hypertension and dyslipidemia. The most recent direct
comparison of cardiovascular risk factors between the general
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Figure 2. Prevalence of dyslipidemia (we defined dyslipidemia as total cholesterol [TC] ≥240 mg/dL, low-
density lipoprotein [LDL-C] cholesterol ≥160 mg/dL, high-density lipoprotein [HDL-C] cholesterol <40 mg/
dL, triglycerides [TG] ≥200 mg/dL, or taking lipid-modifying medications, according to the 2007 Chinese
guidelines on the prevention and treatment of dyslipidemia) and prevalence of each component, in China
and the United States (US), from 2011 to 2012.
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populations of China and the United States used InterAsia
and NHANES data from 1999 to 20015; more recent studies
focused on risk factors solely within China,34 compared
China with other low- and middle-income countries,35 or used
data from disease registry participants.36 Such strategies
yielded incomplete information about China’s population-level
risk profile. A third advantage of our study is the application
of consistent methods across multiple risk factors. By
reporting biomarker distributions, as well as awareness,
treatment, and control rates of multiple risk factors, our
study provides a broad view of the relative role of different
risk factors in prevention efforts. Most previous studies did
not address awareness, treatment, and control rates, or they
addressed those parameters for only one cardiometabolic
risk factor.34
Our study has potential limitations. First, our data relied on
cross-sectional observations, which cannot capture changing
trends. However, our comparative analysis of CHARLS and
NHANES provides an accurate and up-to-date view of
population-level estimates for Chinese adults aged ≥45 years,
especially in comparison with a Western country. Moreover,
data from more recent iterations of CHARLS and NHANES will
enable comparisons of future trends in risk factor prevalence
and prevention. Second, there is a difference in blood
pressure recording methods between the 2 cohorts. Prior
literature suggests that an automated blood pressure device
may systematically underestimate blood pressure.37 If the
automated measurement method of the CHARLS cohort has
led to systematically lower blood pressure recordings, then
the higher blood pressure in China compared with the United
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Figure 3. Mean fasting plasma glucose and prevalence of diabetes mellitus, in China and the United States (US), from 2011 to 2012.
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Figure 4. Mean body mass index (BMI) and prevalence of BMI categories, in China and the United States (US), from 2011 to 2012.
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States may have been underestimated. Third, hs-CRP mea-
sures were calculated from 2009 to 2010 NHANES data
because the 2010 to 2011 survey did not measure hs-CRP as
part of its laboratory testing. Finally, we did not assess diet
and physical activity in our study because they were not
measured in CHARLS.
In conclusion, China has a lower prevalence of cardiovas-
cular risk factors, but the burden is higher for hypertension
and not different for lipids because of differences in treatment
between the 2 countries. Moreover, the greater burden of
hypertension in China, attributable to poor detection and
treatment, may be responsible for China’s high stroke
prevalence. The low rates of awareness, treatment, and
control of hypertension provide an exceptional opportunity for
China to reduce risk in its population.
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sion, dyslipidemia, diabetes mellitus, overweight, and obesity) in
China and the United States (US), from 2011 to 2012.
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SUPPLEMENTAL MATERIAL 
Figure S1. Construction of the study populations in China and the US in 2011-2012 
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